Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 122,196

Document Document Title
WO/2017/069182A1
The purpose of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA ...  
WO/2017/069270A1
Provided is a novel compound or a pharmaceutically acceptable salt thereof that is useful for treating or preventing, on the basis of the PAM effects of the GABAB receptor, diseases such as autism spectrum disorder, fragile X syndrome, s...  
WO/2017/067870A1
The present invention relates to a pharmaceutical composition comprising a combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, said combination having a synergistic effect in the treatment of pain.  
WO/2017/070589A1
Disclosed herein are compositions and methods for the diagnosis and treatment of CNS autoimmune diseases such as MS. The methods of treatment may include administering to the subject at least one of an LTβR inhibitor, a CXCR2 inhibitor,...  
WO/2017/069980A1
The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, an...  
WO/2017/067527A1
The present invention relates to a benzobicyclon compound as presented in formula (I) or pharmaceutically acceptable salts thereof. Also disclosed are a preparation method for said compound, pharmaceutical compositions containing the ben...  
WO/2017/070525A1
In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise adminis...  
WO/2017/069275A1
The present invention provides a novel compound having excellent inhibitory action against KAT II, a production method therefor, a use therefor, and a pharmaceutical composition, or the like, that includes the compound. Provided is the c...  
WO/2017/069226A1
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...  
WO/2017/069173A1
Provided is a compound that has cholinergic muscarinic M1 receptor positive allosteric modulator activity and is useful as a medicine, e.g., a preventative or treatment agent for Alzheimer's disease, schizophrenia, pain, sleep disorders,...  
WO/2017/066368A1
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment...  
WO/2017/064512A1
Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preve...  
WO/2017/066421A1
Provided are methods of treating cognitive impairment and/or psychosis and/or movement disorders by administering a pharmaceutical composition of eplivanserin or a pharmaceutically acceptable salt thereof to a subject in need thereof.  
WO/2017/066747A1
Methods and compositions for treating gastrointestinal inflammation in a subject are provided.  
WO/2017/064488A1
The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing th...  
WO/2017/066626A1
The disclosure provides an injectable neurosteroid nanoparticle formulation comprising nanoparticles having a D50 of less than 2000 nm the nanoparticles comprising a neurosteroid of Formula I, where the variables R1-R9 and X are defined ...  
WO/2017/064688A1
The present invention offers an effective alternative method for treating neurological disorders, preferably those induced by a nerve injury or by a neurodegenerative process. The present invention is the first to show that a substantial...  
WO/2017/066366A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various ...  
WO/2017/066488A1
Provided herein are methods and compositions for effective treatment or prevention of pain, which also reduce or eliminate adverse effects associated with an opioid analgesic. In addition, provided herein are methods and compositions for...  
WO/2017/066590A1
This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need the...  
WO/2017/066444A1
Methods for treating learning disabilities associated with fetal alcohol syndrome and other neurological disorders by administering SK channel blockers, antagonists, inhibitors or modifiers like tamapin.  
WO/2017/064876A1
Provided is a prophylactic and therapeutic agent for Rett syndrome (RTT). A medicinal composition that comprises ghrelin and a pharmacologically acceptable carrier; and a prophylactic and therapeutic agent for RTT that comprises a therap...  
WO/2017/064098A1
The present invention relates to the use of naltrexone for the manufacture of a medicament for the treatment of somatoform pain disorder or persistent pain disorder. The medication is characterized by significant reduction of the symptoms.  
WO/2017/065314A1
The present invention pertains to a method for producing a royal jelly fraction, the method including eluting royal jelly in water and obtaining a residue, eluting the resulting residue in 50% ethanol and obtaining a residue, then elutin...  
WO/2017/063581A1
Provided is an oral preparation for cardiovascular diseases containing a compound 1, wherein the oral preparation is prepared into a large tablet by means of a dry granulation process, the large tablet comprises the compound 1, a filler,...  
WO/2017/066729A1
Provided are novel methods for the treatment or prophylaxis of pain in a feline in need thereof comprising administering to the feline an effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically accep...  
WO/2017/065602A1
The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pha...  
WO/2017/066730A1
Provided are novel methods for the treatment or prophylaxis of pain in an equine in need thereof comprising administering to the equine an effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acce...  
WO/2017/066204A1
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-bin...  
WO/2017/060870A1
The present invention relates to new combinations of treatments for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-O-methyltransferase (COMT) inhibitors.  
WO/2017/062875A1
Compositions and methods for administration of local anesthetics that are delivered by a single injection and enable repeated on-demand or high influx analgesia over extended periods have been developed. Pharmaceutical compositions inclu...  
WO/2017/062974A1
Provided are methods for treatment and prevention of ischemia- reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may...  
WO/2017/060530A1
The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said com...  
WO/2017/062657A1
Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging gro...  
WO/2017/060287A1
The present invention relates to a process for the preparation of an amide from a carboxylic acid chloride and an organic molecule comprising both a primary amine group and a tertiary amine group, wherein the nitrogen atom of the tertiar...  
WO/2017/060510A1
The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular, the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof comp...  
WO/2017/059966A1
The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or pro...  
WO/2017/059965A1
The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or pro...  
WO/2017/059554A1
The present invention relates to a method and use of the AAV-XBP1S/GFP virus in the prevention and treatment of amyotrophic lateral sclerosis, as presented in the in vivo studies in figure 6/9.  
WO/2017/059485A1
The present invention relates to compositions and methods for protecting and/or promoting repair of the nervous system. In particular, the present invention relates to the use of muramyl dipeptide crosslinked to form a microparticle for ...  
WO/2017/062682A3
The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.  
WO/2017/062568A1
The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).  
WO/2017/062270A1
Methods of diagnosis and methods of treatment and prevention for autism spectrum disorder are provided using decoy antigens to maternal brain-reactive antibodies.  
WO/2017/060290A1
The present invention relates to a crystalline forms of encenicline hydrochloride and a process for their preparation. The invention also concerns a pharmaceutical compositions comprising an effective amount of the crystalline form of en...  
WO/2017/060406A1
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ in...  
WO/2017/062238A1
The present invention provides methods and compositions for diagnosing and treating intellectual disability (ID). The invention also provides methods and compositions for developing and using in-vitro and in vivo models for diagnosis and...  
WO/2017/059486A1
The present invention relates to compositions and methods for the treatment of epilepsy. In particular, the present invention relates to the use of muramyl dipeptide crosslinked to form a microparticle for reducing the frequency and/or s...  
WO/2017/060202A1
The present invention relates to compounds of formula I; wherein R1' is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1 and R1 may form together a l,l-dioxo-tetrahydro-thiophen-3-yl ring; R is hydrogen, methyl, ethyl, is...  
WO/2017/060750A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of pathologies of the myelin, including multiple sclerosis disease.  
WO/2017/062682A2
The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.  

Matches 201 - 250 out of 122,196